Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.

Details

Serval ID
serval:BIB_26325EFBDC53
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Journal
Neuro-oncology
Author(s)
Klein M., Drijver A.J., van den Bent M.J., Bromberg J.C., Hoang-Xuan K., Taphoorn MJB, Reijneveld J.C., Ben Hassel M., Vauleon E., Eekers DBP, Tzuk-Shina T., Lucas A., Freixa S.V., Golfinopoulos V., Gorlia T., Hottinger A.F., Stupp R., Baumert B.G.
ISSN
1523-5866 (Electronic)
ISSN-L
1522-8517
Publication state
Published
Issued date
05/05/2021
Peer-reviewed
Oui
Volume
23
Number
5
Pages
803-811
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to determine whether TMZ is associated with less impaired memory functioning.
Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and subsequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and over time.
Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treatment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated with RT gross, clinical, or planned target volumes.
In patients with high-risk low-grade glioma there is no indication that in the first year after treatment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.
Keywords
Antineoplastic Agents, Alkylating/therapeutic use, Brain Neoplasms/drug therapy, Brain Neoplasms/radiotherapy, Glioma/drug therapy, Glioma/radiotherapy, Humans, Progression-Free Survival, Temozolomide/therapeutic use, chemotherapy, low-grade glioma, memory functioning, radiotherapy
Pubmed
Open Access
Yes
Create date
09/11/2020 10:28
Last modification date
22/05/2021 6:34
Usage data